Feb 9, 2026 8:00 am EST bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
Jan 7, 2026 8:00 am EST bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
Dec 3, 2025 8:00 am EST bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
Nov 5, 2025 8:00 am EST bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
Oct 28, 2025 8:00 am EDT bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
Oct 20, 2025 8:00 am EDT bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
Oct 16, 2025 8:00 am EDT bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
Oct 15, 2025 8:00 am EDT bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
Oct 9, 2025 1:00 pm EDT bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
